ATE460176T1 - Mikrosomvakzin - Google Patents

Mikrosomvakzin

Info

Publication number
ATE460176T1
ATE460176T1 AT04743611T AT04743611T ATE460176T1 AT E460176 T1 ATE460176 T1 AT E460176T1 AT 04743611 T AT04743611 T AT 04743611T AT 04743611 T AT04743611 T AT 04743611T AT E460176 T1 ATE460176 T1 AT E460176T1
Authority
AT
Austria
Prior art keywords
vaccin
microsome
mhc
fragments
protein
Prior art date
Application number
AT04743611T
Other languages
English (en)
Inventor
Ping Wang
Suling Li
Original Assignee
Queen Mary & Westfield College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary & Westfield College filed Critical Queen Mary & Westfield College
Application granted granted Critical
Publication of ATE460176T1 publication Critical patent/ATE460176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04743611T 2003-08-01 2004-07-30 Mikrosomvakzin ATE460176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318096.5A GB0318096D0 (en) 2003-08-01 2003-08-01 Vaccine
PCT/GB2004/003285 WO2005011730A1 (en) 2003-08-01 2004-07-30 Microsome vaccine

Publications (1)

Publication Number Publication Date
ATE460176T1 true ATE460176T1 (de) 2010-03-15

Family

ID=27799668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743611T ATE460176T1 (de) 2003-08-01 2004-07-30 Mikrosomvakzin

Country Status (8)

Country Link
US (2) US7498046B2 (de)
EP (1) EP1648498B1 (de)
JP (1) JP4903043B2 (de)
CN (1) CN1856322A (de)
AT (1) ATE460176T1 (de)
DE (1) DE602004025943D1 (de)
GB (1) GB0318096D0 (de)
WO (1) WO2005011730A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004518A1 (en) * 2004-07-02 2006-01-12 Avaris Ab Method for the genetic activation of cells and uses of said cells
GB0502065D0 (en) * 2005-02-01 2005-03-09 Queen Mary & Westfield College Assay method
JP5564249B2 (ja) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
EP2197908A2 (de) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc-multimere in tuberkulose-diagnostika, -impfstoff und therapeutika
EP2250189A4 (de) * 2008-02-26 2012-07-04 Univ California Gylcopeptide sowie verfahren zu ihrer herstellung und verwendung
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
CA2758213C (en) * 2008-04-10 2017-08-15 Thrombosis Research Institute Anti-atheroma vaccine
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
US7821149B2 (en) * 2008-09-18 2010-10-26 Moshe Meller Airborne stabilized wind turbines system
US10369204B2 (en) * 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
BRPI0919882A8 (pt) 2008-10-30 2017-09-19 Caris Life Sciences Luxembourg Holdings Métodos para avaliar padrões de rna
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
CN107254538A (zh) 2008-11-12 2017-10-17 卡里斯生命科学瑞士控股有限责任公司 使用外来体来确定表现型的方法和系统
US10265389B2 (en) * 2009-01-08 2019-04-23 International Institute Of Immunology, Inc. Cancer antigen eEF2
USD642437S1 (en) * 2009-10-12 2011-08-02 Jackel International Limited Drinking cup
USD642865S1 (en) * 2009-10-12 2011-08-09 Jackel International Limited Drinking cup
KR20130056855A (ko) 2010-03-01 2013-05-30 카리스 라이프 사이언스 룩셈부르크 홀딩스 치료진단용 생물학적 지표들
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
JP6294221B2 (ja) 2011-03-31 2018-03-14 アー・デー・ツェー・セラピューティクス・エス・アー 腎臓関連抗原１に対する抗体およびその抗原結合性フラグメント
TR201908872T4 (tr) 2012-01-09 2019-07-22 Adc Therapeutics Sa Üçlü negatif meme kanserini tedavi etmek için ajanlar.
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
KR20210088594A (ko) * 2018-10-21 2021-07-14 더 유니버시티 오브 캔사스 치료학적 전달 플랫폼을 생성하는 방법
EP3898666A2 (de) 2018-12-17 2021-10-27 Immudex ApS Panel mit borrelia-mhc-multimeren
CN110922492B (zh) * 2019-12-18 2022-02-15 重庆医科大学 融合肽、ctp介导的诱导cml细胞免疫应答的dc疫苗及其制备方法
WO2023156532A1 (en) * 2022-02-18 2023-08-24 Servicio Andaluz De Salud ISOLATED PLASMA MEMBRANE-DERIVED VESICLES (PMdV) FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ230424A (en) 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
ATE459339T1 (de) * 1998-10-20 2010-03-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
EP1290016A2 (de) * 2000-06-15 2003-03-12 Purdue Research Foundation Impfstoff gegen kongenitales tremor bei schweinen
CA2433194C (en) * 2000-10-10 2012-04-03 The Board Of Regents Of The University Of Oklahoma Comparative ligand mapping from mhc positive cells
US20020122820A1 (en) * 2001-01-16 2002-09-05 Hildebrand William H. Soluble MHC artificial antigen presenting cells

Also Published As

Publication number Publication date
JP4903043B2 (ja) 2012-03-21
HK1093014A1 (en) 2007-02-23
JP2007501207A (ja) 2007-01-25
US20070184022A1 (en) 2007-08-09
US7498046B2 (en) 2009-03-03
EP1648498B1 (de) 2010-03-10
DE602004025943D1 (de) 2010-04-22
GB0318096D0 (en) 2003-09-03
WO2005011730A8 (en) 2005-12-01
US20090232766A1 (en) 2009-09-17
CN1856322A (zh) 2006-11-01
EP1648498A1 (de) 2006-04-26
WO2005011730A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
ATE460176T1 (de) Mikrosomvakzin
CR7875A (es) Variantes de inmunoglobina y usos de esto
FR20C1016I1 (de)
EP1732581A4 (de) Polypeptidtransduktion und fusogene peptide
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
IS7499A (is) Mennsk mótefni gegn beta-amýloíðpeptíðum
DK1680443T3 (da) Stabiliserede alfa-helix-peptider og anvendelser heraf
DK1620456T3 (da) Hla-a2 tumor-associerede antigen-peptider og præparater
ATE480567T1 (de) Hochkonzentrierter antikörper und proteinformulierungen
EP1490094A4 (de) Antikörper-fusionsproteine: wirksame adjuvantien bei der proteinvakzination
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
DK1670823T3 (da) Kimært mhc-protein og oligomer deraf til specifik målretning
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ATE509025T1 (de) ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
DK1504036T3 (da) Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet
HUP0300997A2 (hu) A MIA-fehérje alkalmazása immunterápiában
NO961423D0 (no) Oligopeptider avledet fra C-reaktive proteinfragmenter
DE602004015141D1 (de) Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe
ATE414540T1 (de) Impfstoffe gegen allergien
EP1802778A4 (de) Hcv-antigene zur mehrfachen epitopfusion mit modifizierten proteolytischen spaltungsorten und verwendungen davon
NO20044105L (no) VEGF peptider og anvendelse derav
ATE506433T1 (de) Prozessierung von peptiden und proteinen
DE60128374D1 (de) Varianten des hauptallergen par j 2 von parietaria judaica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties